Fibrosarcoma is a rare type of soft tissue malignant tumor composed solely of fiber-forming connective tissue called fibroblasts. Although this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years. Individuals, who are suffering from genetic health conditions such as nevoid basal cell carcinoma syndrome, retinoblastoma, are more prone to have fibrosarcoma. However, the precise cause of the disease is unknown. Individuals going through radiation treatment or suffering from lymphedema or getting exposed to chemicals such as arsenic, or thorium dioxide vinyl chloride are more likely to suffer from fibrosarcoma. This disease is symptomized by muscular pain, which increases exponentially with time. It is diagnosed by bone lesions in the radiograph, followed by advanced imaging and laboratory test and confirmed by biopsy results. Treatment of the disease depends on the stage of the tumor during diagnosis. Surgery and radiation therapy are the treatment used for fibrosarcoma. Currently, a limited number of treatment methods and various side effects of chemotherapy such as hair loss or low blood platelet count are propelling demand for research and development activities in fibrosarcoma treatment.
Get PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
Fibrosarcoma Drugs Market Driver
Increasing research activities are expected to fuel the growth of the fibrosarcoma drugs market over the forecast period. Fibrosarcoma being a malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently, available chemotherapy includes side effects such as acquiring multi-drug resistance (MDR), severe side effects, and a high rate of reoccurrence, which in turn demands a safer drug for chemotherapy.
For instance, Loxo Oncology Inc., 2017, received US FDA approval for an investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treating individuals suffering from cancers that have acquired resistance to primary TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced a partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, a clinical trial for targeted drug delivery, and genetic profile-based medication are expected to boost the growth of the fibrosarcoma drugs market over the forecast period.
The increasing prevalence of fibrosarcoma is expected to augment the growth of the fibrosarcoma drugs market. According to the American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed with primary bone cancer in the U.S. out of which 4% of adults are suffering from fibrosarcoma, and the prevalence of the disease is higher in men than in women. Currently, the diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, raising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel the growth of the fibrosarcoma drugs market.
Request PDF Brochure with Latest Insights @
Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with fewer side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving the growth of the fibrosarcoma drug market. Key players, as well as government organizations such as the Nation Cancer Institute or American Society of Clinical Oncology, sponsors or collaborate for the development of novel therapies and drugs. For instance, Bayer partners with loxo oncology to develop and commercialize cancer treatments. Bristol-Myers Squibb Company took over IFM Therapeutics, 2017, to have right on preclinical stimulator of interferon genes (STING) and NLRP3 agonist programs. This is focused on advancing the innate immune response for tumors.
Fibrosarcoma Drugs Market- Regional Analysis
The global fibrosarcoma market is projected to hold a dominant position in North America over the forecast period, due to increasing research activities leading to better fibrosarcoma treatment. Furthermore, well-developed healthcare infrastructure is fuelling the growth of the fibrosarcoma market. The Asia Pacific is expected to be the fastest-growing market over the forecast period due to developing healthcare infrastructure and rising awareness regarding conditions of fibrosarcoma.
Fibrosarcoma Drugs Market- Competitor
Major players operating in the fibrosarcoma drugs market include Celon Laboratories Pvt. Ltd., Johnson & Johnson., Pfizer Limited, Eli Lilly and Company, Baxter International Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company, and Cadila Healthcare Limited.
Reasons to Buy this Fibrosarcoma Drugs Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Fibrosarcoma Drugs market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Fibrosarcoma Drugs market
➡Leading company profiles reveal details of key Fibrosarcoma Drugs market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Fibrosarcoma Drugs market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat USD 2000 Off @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Fibrosarcoma Drugs Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Fibrosarcoma Drugs Industry Impact
Chapter 2 Global Fibrosarcoma Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Fibrosarcoma Drugs (Volume and Value) by Type
2.3 Global Fibrosarcoma Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Fibrosarcoma Drugs Sales, Consumption, Export, Import by Regions
Chapter 5 North America Fibrosarcoma Drugs Market Analysis
Chapter 6 East Asia Fibrosarcoma Drugs Market Analysis
Chapter 7 Europe Fibrosarcoma Drugs Market Analysis
Chapter 8 South Asia Fibrosarcoma Drugs Market Analysis
Chapter 9 Southeast Asia Fibrosarcoma Drugs Market Analysis
Chapter 10 Middle East Fibrosarcoma Drugs Market Analysis
Chapter 11 Africa Fibrosarcoma Drugs Market Analysis
Chapter 12 Oceania Fibrosarcoma Drugs Market Analysis
Chapter 13 South America Fibrosarcoma Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Fibrosarcoma Drugs Business
Chapter 15 Global Fibrosarcoma Drugs Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027